News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Joins Race To Copy Sanofi (France) (SAN.PA)'s Lantus


2/11/2014 8:22:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product. Merck, which is working with Samsung Bioepis on the project, said on Monday its version of glargine - the generic name for Lantus - would soon enter late-stage Phase III studies in type 1 and type 2 diabetes. Until now, the only company with a copycat version of Lantus in late-stage clinical development has been Eli Lilly.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES